These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31109870)
1. High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay. Tien CJ; Carlson DJ; Nath R; Chen ZJ Brachytherapy; 2019; 18(5):701-710. PubMed ID: 31109870 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy. Pop LA; Millar WT; Visser AG; van der Kogel AJ Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872 [TBL] [Abstract][Full Text] [Related]
3. Radiobiological evaluation of the stepping-source effect in single-fraction monotherapy high-dose-rate prostate brachytherapy. Tien CJ; Chen Z Brachytherapy; 2023; 22(5):593-606. PubMed ID: 37263898 [TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
5. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate. Sminia P; Schneider CJ; Fowler JF Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810 [TBL] [Abstract][Full Text] [Related]
6. Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models. Mavroidis P; Milickovic N; Cruz WF; Tselis N; Karabis A; Stathakis S; Papanikolaou N; Zamboglou N; Baltas D Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):216-23. PubMed ID: 24331667 [TBL] [Abstract][Full Text] [Related]
7. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. King CR; DiPetrillo TA; Wazer DE Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389 [TBL] [Abstract][Full Text] [Related]
8. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer. Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161 [TBL] [Abstract][Full Text] [Related]
9. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning. Guerrero M; Li XA Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060 [TBL] [Abstract][Full Text] [Related]
10. Impact of tumor repopulation on radiotherapy planning. Wang JZ; Li XA Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615 [TBL] [Abstract][Full Text] [Related]
11. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources. Baltas D; Lymperopoulou G; Löffler E; Mavroidis P Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569 [TBL] [Abstract][Full Text] [Related]
12. The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery. Kann BH; Yu JB; Stahl JM; Bond JE; Loiselle C; Chiang VL; Bindra RS; Gerrard JL; Carlson DJ J Neurosurg; 2016 Dec; 125(Suppl 1):154-159. PubMed ID: 27903196 [TBL] [Abstract][Full Text] [Related]
13. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate. Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579 [TBL] [Abstract][Full Text] [Related]
14. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745 [TBL] [Abstract][Full Text] [Related]
16. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Li XA; Wang JZ; Stewart RD; DiBiase SJ Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099 [TBL] [Abstract][Full Text] [Related]
17. How low is the alpha/beta ratio for prostate cancer? Wang JZ; Guerrero M; Li XA Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054 [TBL] [Abstract][Full Text] [Related]
18. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer. Lennernäs B; Albertsson P; Edgren M; Nilsson S Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588 [TBL] [Abstract][Full Text] [Related]
19. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698 [TBL] [Abstract][Full Text] [Related]
20. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. Yoshioka Y; Yoshida K; Yamazaki H; Nonomura N; Ogawa K J Radiat Res; 2013 Sep; 54(5):781-8. PubMed ID: 23543798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]